Abstract
The most rigorous and accurate approach to evaluating clinical events in cancer screening studies is to use data obtained through medical record abstraction (MRA). Although MRA is complex, the particulars of the procedure—such as the specific training and quality assurance processes, challenges of implementation, and other factors that influence the quality of abstraction—are usually not described in reports of studies that employed the technique. In this paper, we present the details of MRA activities used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which used MRA to determine primary and secondary outcomes and collect data on other clinical events. We describe triggers of the MRA cycle and the specific tasks that were part of the abstraction process. We also discuss training and certification of abstracting staff, and technical methods and communication procedures used for data quality assurance. We include discussion of challenges faced and lessons learned.
Keywords: Abstraction, medical record abstraction, medical record requests, quality assurance, screening.
Reviews on Recent Clinical Trials
Title:Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Volume: 10 Issue: 3
Author(s): Bazzi Latifa, Lamerato Lois E, Varner Julie, Shambaugh Vicki L., Cordes Jill E, Ragard Lawrence R and Marcus Pamela M
Affiliation:
Keywords: Abstraction, medical record abstraction, medical record requests, quality assurance, screening.
Abstract: The most rigorous and accurate approach to evaluating clinical events in cancer screening studies is to use data obtained through medical record abstraction (MRA). Although MRA is complex, the particulars of the procedure—such as the specific training and quality assurance processes, challenges of implementation, and other factors that influence the quality of abstraction—are usually not described in reports of studies that employed the technique. In this paper, we present the details of MRA activities used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which used MRA to determine primary and secondary outcomes and collect data on other clinical events. We describe triggers of the MRA cycle and the specific tasks that were part of the abstraction process. We also discuss training and certification of abstracting staff, and technical methods and communication procedures used for data quality assurance. We include discussion of challenges faced and lessons learned.
Export Options
About this article
Cite this article as:
Latifa Bazzi, Lois E Lamerato, Julie Varner, Vicki L. Shambaugh, Jill E Cordes, Lawrence R Ragard and Pamela M Marcus, Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150731145421
DOI https://dx.doi.org/10.2174/1574887110666150731145421 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Characterization, Anti-proliferative Evaluation, and DNA Flow Cytometry Analysis of Some 2-Thiohydantoin Derivatives
Mini-Reviews in Medicinal Chemistry Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Research Development of End Traction Shoulder Rehabilitation Device
Recent Patents on Mechanical Engineering Interleukin-21 in Immune and Allergic Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Notice of Withdrawal
Current Cancer Drug Targets Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Susceptibility Risk Alleles of -238G/A, -308G/A and -1031T/C Promoter Polymorphisms of TNF-α Gene to Uterine Leiomyomas
Recent Advances in DNA & Gene Sequences (Discontinued) Editorial:Tubulin-targeted Cancer Chemotherapeutics: Advances and Challenges
Current Topics in Medicinal Chemistry Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Future of Protease Activity Assays
Current Pharmaceutical Design Recognition and Function of HumanγδT Cells: Application for Tumor Immunotherapy
Current Immunology Reviews (Discontinued) MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences